44 results about "Pulmonary infection" patented technology

The invention relates to the technical field of medical data mining, in particular to a postoperative pulmonary infection prediction method and system.The postoperative pulmonary infection prediction method comprises the following steps that a continuous data set is formed by collecting breathing parameters and conducting alignment completion, tidal volume and blood oxygen response delay characteristics are extracted through sliding analysis, and a functional abnormal pulmonary segment is located through local anomaly recognition; and fusing physiological and anatomical features to establish a spatial probability map, extracting a respiratory variation coefficient and a risk feature regression analysis confidence index, and outputting an infection risk early warning list with anatomical positioning. According to the method, data faults are eliminated through timestamp alignment to improve the reliability of time sequence association, the breathing compensation capability is quantified through multi-scale window analysis dynamic coupling, lesion avoidance feature masking is accurately positioned through local anomaly detection, and the result interpretability is enhanced through combination of multi-modal feature fusion and space mapping. The three-stage progressive mechanism improves the prediction precision and timeliness, and provides a decision basis with both time sensitivity and anatomical orientation for clinic.

The antibody disclosed by the invention can specifically target high-virulence klebsiella pneumoniae of different serotypes, and specifically targets klebsiella pneumoniae of K1 and K2 serotypes. The antibody disclosed by the invention can be combined with high-toxicity klebsiella pneumoniae extracellular capsular polysaccharide with high affinity, has very strong neutralizing activity on klebsiella pneumoniae, and can mediate complement and mature neutrophil to neutralize and kill bacteria in an in-vitro killing experiment, so that the bacterial density is reduced, and the killing effect is improved. The traditional Chinese medicine composition can effectively prevent and treat high-toxicity klebsiella pneumoniae clinical infection and effectively improve pulmonary infection, provides a way for solving the problems of klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance in preventing, diagnosing and treating klebsiella pneumoniae infection, and has important value in development of a new generation of klebsiella pneumoniae medicine.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The invention discloses application of a TIMM10 gene as a target spot in resisting influenza A virus, and belongs to the technical field of biological medicine. Specifically, TIMM10 gene knock-down is carried out on A549 cells, and it is found that in the cells with knocked-down TIMM10, expression of main protein hemagglutinin and nucleoprotein of influenza viruses is remarkably improved, and virus RNA and virus titer in supernate are also remarkably increased; overexpression of TIMM10 in A549 cells inhibits replication and infectivity of IAV in the cells. A further in-vivo experiment is carried out through a TIMM10 whole body knockout heterozygote mouse, and a result shows that the lung of the TIMM10 heterozygote mouse shows more serious pulmonary infection, including pulmonary hemorrhage and increased inflammatory cell infiltration. Based on the effect of TIMM10 in the influenza virus infection process, the invention provides a new therapeutic target, and provides a new thought and direction for developing a therapeutic strategy for IAV in the future.

The invention discloses an integrated nano-enzyme with multiple response mechanism synergism, and a preparation method and application thereof. A Z-type heterojunction based on boron nanosheets (B NSs) and rare earth doped iron phosphide (Nd < 0.02 > Fe < 1.98 > P) is constructed for the first time, and CTAB is used for surface modification to obtain a ternary composite nano-enzyme (BFC); according to the present invention, the material is endowed with the multi-response ability (POD / GSHOx enzyme activity synergistic activation) on the bacterial infection microenvironment (low pH and high H2O2), and the nano-enzyme has excellent acoustic-magnetic responsiveness, can break through the depth limitation, and can achieve the precise and controllable generation of the reactive oxygen species (ROS). Under the acidic microenvironment of pulmonary infection, the activity of peroxidase (POD) and glutathione oxidase (GSHOx) is activated, so that efficient and controllable synergistic killing is performed on bacteria.

The present invention discloses a combined prediction method for the risk of pulmonary infection after kidney transplantation, comprising the following steps: S1, quantifying a clinical data set; S2, designing a feature extraction network for preoperative static data and extracting features of the preoperative static data; S3, designing a feature extraction network for postoperative dynamic data sequences and extracting features of the postoperative dynamic data sequences; S4, fusing the features obtained in step S3 and the features obtained in step S4; S5, performing binary classification calculation on the fused features obtained in step S5 using a linear classifier, and inversely obtaining an intelligent prediction result of whether there is an infection from the classification result. The present invention can be applied to predicting in advance the occurrence of the risk of pulmonary infection at each time node after kidney transplantation for patients, and providing clinical auxiliary decision-making support for the diagnosis and treatment plan after kidney transplantation.

The invention discloses a severe pulmonary infection sputum sample sampling device, and relates to the technical field of medical sampling instruments.The severe pulmonary infection sputum sample sampling device comprises a sampling tank and a negative pressure pipe, a mounting cabin is fixedly installed on the sampling tank, a filtering module used for filtering sputum sample particles is further arranged outside the sampling tank, and a detection module used for detecting a sputum sample is further arranged on the sampling tank; the sampling tank is connected with the detection module through a transfer pipe, the filtering module comprises a filtering box installed on the mounting cabin in a sealed mode, a sampling pipe used for sucking a sputum sample is arranged on the filtering box, a sputum suction head is fixedly installed at the end, extending out of the filtering box, of the sampling pipe, and filtering holes distributed in an arrayed mode are formed in the side, close to the sputum suction head, of the filtering box. The filter holes are formed in the filter box, and the filter membrane is arranged at the joint of the sampling tank and the mounting cabin, so that secondary filtration of a sputum sample is realized, large particles and fine impurities in the sputum sample can be effectively removed, and a pure sample can be obtained without additional filtration steps.

The application discloses a sputum suction device for patients with lung infection and relates to the technical field of sputum suction devices.The sputum suction device comprises a sputum suction machine body, a sputum storage tank is connected to the sputum suction machine body through an adapter hose, a sputum main pipe is connected to an input end of the sputum storage tank, a cleaning ring pipe is fixedly arranged at an upper end in the sputum storage tank, a plug-in pipe is connected to one end of the sputum main pipe, a cleaning mechanism is arranged in an installation box, and a disinfection mechanism is arranged in the installation box.The plug-in pipe and the cleaning ring pipe are arranged to clean the inside of the sputum storage tank and the sputum main pipe.An ozone generating part is arranged to facilitate the disinfection of the inside of the sputum storage tank and the sputum main pipe.Silica gel hoses are arranged in a wastewater tank, so that the used ozone can further disinfect the waste liquid in the wastewater tank, thereby reducing the spread of bacteria and viruses.

The present application provides a composite sonosensitizer and its bacterial target delivery system BPT-ICG@Bd capable of treating pseudomonas aeruginosa biofilm related infection, wherein the composite sonosensitizer (BPT-ICG) is composed of inorganic sonosensitizer (BPT) and organic sonosensitizer (ICG), Bd is natural gram-negative bacteria predator Bdellovibrio, the composite sonosensitizer (BPT-ICG) is modified to the surface of Bdellovibrio (Bd) by polydopamine to form BPT-ICG@Bd. The high-speed movement characteristics of Bdellovibrio predator gram-negative bacteria are used to destroy the biofilm structure, invade bacteria, and at the same time, the composite sonosensitizer is triggered to produce a large amount of active oxygen by applying ultrasound, so as to quickly remove the biofilm and bacteria, and be used for biofilm related lung infection and bone infection.

The invention discloses a sputum suction connecting tube, and relates to the technical field of medical instruments, in particular to a sputum suction connecting tube which comprises an inner tube, the sputum suction end of the inner tube is slidably sleeved with an outer tube, the front end of the inner tube is wrapped with a buffer layer, and an air cavity is formed between the buffer layer and the inner tube. A negative pressure moving ring capable of moving inwards through negative pressure is arranged on the inner wall of the sputum suction end of the inner tube, and an air bag capable of inflating the air cavity is arranged on the inner side, close to the negative pressure moving ring, of the inner wall of the sputum suction end of the inner tube. The covering cylinder at the end part of the outer tube is flexibly propped against the buffer layer at the front end of the inner tube, so that when the outer tube carries the covering cylinder to enter the upper respiratory tract in advance and is fixed at a preset position, the inner tube can be independently pushed forwards to go deep into the lower respiratory tract, and colonized florae in the upper respiratory tract are effectively prevented from invading the lower respiratory tract along with the sputum suction tube by utilizing the physical isolation effect of the outer tube; the iatrogenic pulmonary infection risk is reduced.

The invention discloses an augmented reality chest surgery grading nursing intervention management method, and relates to the technical field of chest surgery nursing, and the technical scheme is characterized in that the method comprises the following steps: obtaining personalized health record data of a chest surgery patient and operation track data in an AR nursing scene, and obtaining multi-modal time sequence nursing data; judging the real-time fluctuation characteristics of the nursing demand of the patient based on the multi-modal time sequence nursing data to generate a nursing demand fluctuation characteristic data set; constructing an effectiveness evaluation dimension system of thoracic surgery nursing intervention, establishing a corresponding relation set of effectiveness evaluation and nursing grading, and extracting coupling influence coefficients of effectiveness evaluation indexes under different nursing grading standards to obtain a nursing effectiveness coupling coefficient set; the method has the effects of accurately positioning abnormal requirements by combining a fluctuation feature recognition technology, reducing traditional experience judgment nursing deviation, and greatly reducing the risk of complications such as pulmonary infection and poor incision healing.

A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.

The invention relates to the technical field of chronic obstructive pulmonary disease treatment, and discloses a chronic obstructive pulmonary disease patient expectoration assisting and aerosol inhalation integrated device which comprises a main machine, a first connecting pipe is connected to the top of a double-end bent pipe in a penetrating mode, a second connecting pipe is connected to one side of the top of the double-end bent pipe in a penetrating mode, and a first catheter is connected to the top of the first connecting pipe in a penetrating mode. A first catheter is connected to the top of the first connecting pipe in a penetrating mode, a second catheter is connected to the top of the second connecting pipe in a penetrating mode, a connector is connected to one end of the first catheter in a penetrating mode, and a suction nozzle is fixedly arranged at one end of the connector. The operation of expectoration assistance and atomization treatment is respectively carried out through the pipeline of the same channel, meanwhile, the airflow trend and liquid flow of the two are not interfered with each other under the treatment condition of the same channel, different treatment pipelines do not need to be frequently replaced for treatment when a chronic obstructive pulmonary disease patient is treated, the risk of pulmonary infection of the patient is reduced, and the treatment efficiency is improved. The treatment effect is improved.

The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine wherein the clofazimine is provided in the form of a suspension, and processes for their preparation. Furthermore, the present invention provides pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention may be used in the treatment and / or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections.

The utility model discloses an auxiliary device for an artificial airway, which can be used for connecting the artificial airway with a connecting pipeline of external equipment, and comprises a cylinder body and a first connecting piece, a gas flow channel is formed in the cylinder body, and the first connecting piece is arranged at the gas inlet end of the gas flow channel and is used for being detachably connected with the external equipment. The second connecting piece is arranged at the gas outlet end of the gas flow channel and used for being detachably connected with the artificial airway, a heating coating is annularly arranged on the pipe wall in the circumferential direction of the pipe wall, the heating coating is provided with a power supply interface electrically connected with an external power source, and the heating coating is used for heating gas flowing through the gas flow channel. According to the auxiliary device, air in the air flow channel can be uniformly heated, so that air at the temperature suitable for the human body is discharged into the artificial airway from the second connecting piece, discomfort of a patient is avoided, the risk of pulmonary infection of the patient is reduced, the heating coating does not hinder circulation of the air in the air flow channel, and the ventilation efficiency is improved.

The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine wherein the clofazimine is provided in the form of dry powder, and processes for their preparation. In addition, the present invention provides a pharmaceutical combination comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided herein are useful for the treatment and / or prevention of pulmonary fungal infections and pulmonary infections caused by mycobacteria and other gram-positive bacteria.

The present application relates to the application of sanguinarine in the preparation of drugs for preventing and treating rare clinical fungal infection diseases. Apiotrichum mycotoxinivorans has been confirmed to have the ability to infect humans, and current research confirms that the fungus is at least associated with postoperative pulmonary infection and blood infection diseases. Since the above fungus is still a rare clinical pathogenic bacterium, there is no clear and feasible treatment drug at present. Based on the advantages of low toxicity and side effects of natural drugs and mild efficacy, the present application screens natural drugs with bacteriostatic effect, and provides the application of sanguinarine as a fungus inhibitor, which has good clinical application prospect.

The present invention relates to 3-(phenylsulfonyl)-[1,2,3]triazolo[1,5a]quinazolin-5(4H)-one derivatives and pharmaceutical compositions thereof, as well as their use in a method for reducing the virulence of bacteria (preferably Staphylococcus aureus) expressing accessory gene regulator A (AgrA) or an ortholog of AgrA; their use in a method for inhibiting quorum sensing in bacteria, preferably Staphylococcus aureus; and their use in a method for preventing or treating diseases caused or exacerbated by bacteria, preferably Staphylococcus aureus, such as skin or lung infections, for example, atopic dermatitis, Netherton syndrome, or psoriasis in a subject. The compounds have shown excellent ability to inhibit the transcription of genes under the control of the P3 promoter in Staphylococcus aureus, even in the presence of human serum or human serum albumin.

The invention belongs to the field of medicine, and particularly relates to a traditional Chinese medicine composition and a preparation method and application thereof. The invention relates to a preparation method of an anti-aging agent. Comprising the following components in parts by weight: 60-150 parts of astragalus membranaceus, 8-15 parts of angelica sinensis, 6-12 parts of radix paeoniae rubra, 8-12 parts of peach kernel, 6-10 parts of safflower, 6-12 parts of radix bupleuri, 10-20 parts of radices trichosanthis, 12-25 parts of salvia miltiorrhiza, 6-12 parts of ligusticum wallichii, 15-30 parts of radix rehmanniae recen, 8-15 parts of radix achyranthis bidentatae, 8-12 parts of fructus aurantii, 8-12 parts of platycodon grandiflorum, 5-10 parts of liquorice, 10-30 parts of folium mori, 8-15 parts of almond, 8-15 parts of scutellaria baicalensis, 10-30 parts of folium eriobotryae, 3-10 parts of raw rhubarb, 6-20 parts of bulbus fritillariae cirrhosae and 3-12 parts of pseudo-ginseng. Optionally, the composition also comprises 6-12 parts of lumbricus. Optionally, the composition further comprises 3-9 parts of ground beetles. Postoperative intracranial and pulmonary infection can be prevented, the pathological basis of nerve injury is improved, neural function recovery is promoted, and patient prognosis is improved.

The present invention relates to a compound of formula (I) for use in a method of treatment of a viral lung infection and / or of an adverse immune response to a viral lung infection, the method comprising administering to a subject in need thereof an effective amount of said compound, or to a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable support for use in a method as defined above.

The invention relates to the field of biological medicine, in particular to application of a recombinant protein in preparation of a pseudomonas aeruginosa vaccine, which is characterized in that the recombinant protein comprises an outer membrane carboxylate channel K6 protein of pseudomonas aeruginosa, and the pseudomonas aeruginosa vaccine comprises the recombinant protein and an outer membrane pore protein combination, the recombinant protein is used for improving the immune efficacy of the outer membrane pore protein combination; the outer membrane pore protein combination comprises outer membrane pore protein F and outer membrane pore protein I; wherein the mass ratio of the recombinant protein to the outer membrane pore protein combination is (1-3): 3. The pseudomonas aeruginosa vaccine provided by the invention shows better immune protection efficacy (the bacterial clearance rate can reach 99% or above), is good in safety, and has extremely high application value in prevention and / or treatment of pseudomonas aeruginosa infection (especially pulmonary infection caused by pseudomonas aeruginosa).

The invention relates to a ciprofloxacin dry powder inhalation particle, the dry powder inhalation particle comprises 60-95% by weight of ciprofloxacin hydrochloride and a pharmaceutically acceptable carrier, the mass median aerodynamic diameter (MMAD) of the dry powder inhalation particle is 1-5 [mu] m, and the geometric particle size distribution is that D10 is less than or equal to 2.0 [mu] m, D50 is less than or equal to 4.5 [mu] m, and D90 is less than or equal to 8.0 [mu] m. The dry powder inhalation particle can target high-concentration deposition of a lung infection part, the bioavailability is remarkably improved, and risks of renal toxicity, ototoxicity, drug resistance and the like are reduced.

The invention discloses a novel medical application of sodium new houttuyfonate in prevention and treatment of pathogenic bacteria, including application of sodium new houttuyfonate in preparation of drugs for prevention and treatment of pathogenic fungus infection or drugs for inhibition of pathogenic fungi. The pathogenic fungi are selected from one or more of cryptococcus neoformans, cryptococcus gattii, trichophyton rubrum, trichophyton purple, microsporum canis, candida niticola complex bacteria, candida albicans, trichophyton mentagrophytes and trichophyton broken. Researches show that sodium new houttuyfonate has important significance in preventing and treating infection of different pathogenic bacteria, especially has a remarkable curative effect on cryptococcus neoformans lung infectious diseases and skin traumatic infectious diseases, and compared with traditional antibacterial drugs, the sodium new houttuyfonate is not prone to causing drug resistance of pathogenic bacteria and has a good application prospect. The compound is expected to be developed into a candidate drug for clinically treating different pathogenic bacteria, is efficient, non-toxic and broad-spectrum, is expected to solve the problem of drug resistance of the pathogenic bacteria, and has a good application prospect.

The present invention relates to 3-(phenylsulfonyl)-[1,2,3] triazolo[1,5a]quinazolin-5(4H)-one derivatives and pharmaceutical compositions thereof as well as to their uses in methods of reducing the virulence of bacteria (preferably Staphylococcus aureus) that express accessory gene regulator A (AgrA) or an ortholog of AgrA; in methods of inhibition of the quorum sensing in bacteria, preferably in S. aureus; and in methods for preventing or treating diseases caused or exacerbated by bacteria, preferably by S. aureus, such as skin or lung infections, e.g., wherein said skin infection is atopic dermatitis, Netherton syndrome, or psoriasis in a subject. The compounds exhibited superior ability to inhibit the transcription of genes under the control of the P3 promoter in S. aureus even in the presence of human serum or human serum albumin.

The present invention relates to aconitic acid or a pharmaceutically acceptable salt thereof for use in a method of treating a viral pulmonary infection and / or an adverse immune response to a viral pulmonary infection, the method comprising administering to a subject in need thereof an effective amount of aconitic acid or a pharmaceutically acceptable salt thereof, or to a pharmaceutical composition comprising aconitic acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in a method as defined above.

Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and / or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and / or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and / or combinations thereof as an inhaled dry powder treatment for COVID-19 and / or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and / or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and / or sonodynamic therapy (PDT / SDT).

The invention discloses a sputum excretion nursing device for pulmonary infection of old people and a use method of the sputum excretion nursing device. The sputum excretion nursing device comprises a main control unit, a wearable vest, a multi-mode vibration excretion promoting module, a bionic cough stimulation module, a respiration monitoring and evaluating module and a man-machine interaction unit. The vibration discharge promoting module is integrated in the vest and comprises a miniature unit which can be independently controlled and has high-frequency release and low-frequency clearance functions. The bionic cough stimulation module conducts instantaneous stimulation on the throat through the air bag to induce cough reflex. The respiration monitoring module evaluates the sputum condition in real time. The main control unit intelligently formulates and adjusts a personalized sputum excretion scheme according to the evaluation result, controls the modules to work cooperatively, and quantifies the evaluation result. According to the intelligent sputum excretion device, through the cooperation mechanism of physical release, clearance and nerve stimulation, intelligence, precision, safety and comfort of the sputum excretion process are achieved, and the intelligent sputum excretion device is particularly suitable for sputum excretion nursing of old patients in hospitals or family environments.

The invention provides a sputum excretion device for pulmonary infection of old people, which comprises a control box and a liquid storage assembly arranged on one side of the control box, and the liquid storage assembly is connected with a sputum suction tube; wherein a fixing seat is arranged at the intersection of the control box and the liquid storage assembly, a slidable limiting assembly is arranged on the upper surface of the fixing seat, the liquid storage assembly is placed on the upper surface of the fixing seat, the limiting assembly is pulled upwards while the limiting assembly slides, the limiting assembly moves to the top end of the liquid storage assembly, and the limiting assembly is clamped with the liquid storage assembly under the elastic action of the limiting assembly; a liquid storage bottle is connected with a fixing base, slides in a sliding groove through a limiting assembly, is connected with the liquid storage bottle and makes contact with the outer wall of the liquid storage bottle through the elastic force of a spring ring, and stable limiting force is provided; and the liquid storage bottle is ensured not to loosen or fall off in the vibration process.

Methods and composition for treating or preventing a lung infection, or related symptoms, caused by a fungus using an effective amount of tafenoquine are disclosed. Methods for treating or preventing fungal lung infections, or related symptoms, include administering an effective amount of tafenoquine are disclosed. Kits including tafenoquine and means for testing for a fungal infection are disclosed.